Hemab Therapeutics' Sutacimig Continues to Support Durable Bleed Reduction, Wedbush Says

MT Newswires Live07-14

Hemab Therapeutics' (COAG) sutacimig continues to support clinically meaningful and durable bleed reduction in Glanzmann thrombasthenia, based on the company's phase 2 long-term extension data, Wedbush Securities said in a Tuesday note.

Across the efficacy-evaluable population, sutacimig reduced annualized treated bleeding rate by 47% over the combined treatment and extension periods, with benefit observed across dose levels, bleed locations, and bleed etiologies.

Additionally, the 47% reduction in annualized treated bleeding rate over the combined treatment and extension periods matched the 47% reduction observed during the initial 12-week treatment period alone, supporting a durable effect over extended dosing, according to the note.

The investment firm said that beyond sutacimig, it was encouraged by updates related to HMB-002 in von Willebrand disease and the introduction of HMB-003, reinforcing a "positive view" on the company's bleeding-disorder franchise.

Wedbush reiterated its outperform rating with a $55 price target.

Price: 39.41, Change: -0.10, Percent Change: -0.25

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment